Buy & Sell Novartis AG (NVS) – Novartis AG Price Today
Aura AI Summary
Key Stats
- $292.94BMarket Cap
- HealthSector
- -7.83%3M Drawdown
- $332.96BEnterprise Value
- 3.1%Dividend Yield
- 90% Buy | 10% SellTrading Activity
- 81 daysTypical Hold Time
Novartis AG (NVS) is currently valued at a market capitalization of $292.94B, with an enterprise value of $332.96B. Over the past 52 weeks, Novartis AG has traded between a low of $113.5 and a high of $168.62, highlighting its annual price range. Over the past three months, Novartis AG has recorded a drawdown of -7.83%, reflecting recent price volatility. Novartis AG offers a dividend yield of 3.1%, with the most recent dividend of $4.77 paid on 11 Mar 26. On average, investors hold Novartis AG for approximately 81 days, indicating typical investor behavior on the platform.
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Most Recent News
Nvidia's CEO runs the $5T company with urgency, fearing collapse in 30 days, says Perplexity's CEO.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...

Meta launches AI-powered Facebook Search tool aiming to generate $10B annually and challenge Google.
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...

Cuprina Holdings shares drop 22% after a 112% intraday rally on FDA clearance news.
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
